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A B S T R A C T
Purpose: Whether repeated brief seizures can cause neuronal damage is controversial. Cerebrospinal
ﬂuid (CSF) total tau (T-tau) and phosphorylated tau (P-tau) measurements have been suggested for the
diagnosis of Alzheimer’s disease, and T-tau may also be a marker of axonal damage and neuronal
degeneration. We studied T-tau and P-tau levels and P-tau/T-tau ratio in CSF after epileptic seizures in
order to determine whether they are increased after seizures.
Methods: A total of 54 patients with tonic–clonic or partial secondarily generalized seizures due to
various etiologies were studied and CSF obtained within 48 h after the seizure.
Results: There were no statistical differences in the levels of T-tau (p = 0.09, ANOVA) or P-tau (p = 0.60)
between different etiologic groups or controls. No patients with epilepsy of unknown origin had
abnormal CSF T-tauwhereas 11 patients with acute or remote symptomatic seizures had abnormal T-tau
levels and the P-tau/T-tau ratio showed signiﬁcant differences between the groups and controls
(p = 0.003).
Conclusions: Epileptic seizures with unknown etiology did not increase CSF tau levels. Abnormal tau
levels were associated with either acute or remote symptomatic seizures with known etiology. The
presence of elevated CSF tau increases the probability of symptomatic cause in a patient with a seizure.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Clinical and experimental studies have shown that status
epilepticus may induce neuronal damage, especially in the
hippocampus. Whether repeated brief seizures can cause such
neuronal damage is, however, controversial.1,2 Markers of brain
injury, such as neuron-speciﬁc enolase (NSE) or S-100b protein (S-
100), have been measured in patients with seizures. Increased
levels of NSE have been reported in a subset of epileptic patients.3
However, in our previous study neither NSE nor S-100 was
elevated in serum or cerebrospinal ﬂuid (CSF) after a single tonic–
clonic seizure in patientswith a newly diagnosed seizure disorder.4
Tau is a microtubule-associated protein with a major role in
normal microtubular function in axons. Tau is a phosphoprotein
but abnormally high phosphorylation of tau protein decreases its
ability to promote microtubular assembly. The equilibrium
between phosphorylation and dephosphorylation modulates
cytoskeletal stability and axonal morphology.5 Tau protein is* Corresponding author at: Department of Neurology, University of Tampere, FIN-
33014 Tampere, Finland. Tel.: +358 3 31166783; fax: +358 3 35516164.
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doi:10.1016/j.seizure.2009.04.006primarily localized in axons, and after brain parenchymal damage
its release into CSF may increase.6 Increased levels of CSF total tau
(T-tau) and especially phosphorylated tau (P-tau) are frequently
found in patientswith Alzheimer’s disease (AD) but also in patients
with various neurological diseases, such as traumatic brain injury,7
acute ischemic stroke,8 and viral encephalitis, suggesting that T-
tau CSF levels reﬂect the extent of axonal damage and neuronal
degeneration.9,10 CSF tau levels are very high in patients with
Creuzfeldt–Jakob disease.11
To our knowledge, tau levels have not been previously
measured after epileptic seizures. We hypothesized that CSF tau
levels may be a marker of neuronal damage in patients suffering
from epileptic seizures. Therefore, we studied T-tau and P-tau
levels and P-tau/T-tau ratio in CSF after epileptic seizures due to
various etiologies.
2. Materials and methods
The study was performed at the Emergency Department of
Neurology, Tampere University Hospital, Finland. A total of 54
patients with tonic–clonic or partial secondarily generalized
seizures were included in the study. The patients had either single
or recurrent seizures (the median number of seizures was 1.5).vier Ltd. All rights reserved.
Fig. 1. The individual values of total tau (T-tau) and phosphorylated tau (P-tau) and
P-tau/T-tau ratio in different patient groups and normal controls. ALCO, alcohol
withdrawal; SYMPT, remote symptomatic epilepsy; EPI, cryptogenic focal, or
idiopathic epilepsy; ACU, acute systemic or CNS illness. The horizontal lines
represent the cutoff value for T-tau and P-tau (>60 years).
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female patients with a mean age of 48 years (range 16–88 years).
All patients were fully informed of the risks and potential beneﬁts
of the CSF examination, which was performed to exclude CNS
infection. Informed consent to participate in the study was
obtained from each subject. The study protocol was approved
by the Ethics Committee of Tampere University Hospital.
CSF tau increases with age.12,13 The reference values for tau
have been established for elderly patients (>60 years) in our
laboratory.14 Therefore, we obtained control samples from 31
younger (<60 years) patients with neurological symptoms (e.g.
dizziness, headache) on whom lumbar puncture was performed to
exclude neurological disease. Clinical examination or imaging
studies (computed tomography (CT) or magnetic resonance
imaging (MRI) of the head) revealed no pathological ﬁndings in
control subjects. The mean age in the control group was 40 years
(range 15–56 years).
The patients were divided into groups based on the underlying
etiology of epileptic seizures. The seizures were caused by alcohol
withdrawal in group 1 (ALCO, n = 15). In groups 2 and 3 the
patients had diagnosis of epilepsy. Group 2 (SYMPT, n = 16) had
remote symptomatic epilepsy and in group 3 (EPI, n = 13) the
patients had either cryptogenic focal (n = 10) or idiopathic epilepsy
(n = 3) with no related ﬁndings in brain CT or MRI. The etiology of
remote symptomatic epilepsy (group 2) was tumor in the CNS
(n = 6), post-stroke or post-traumatic epilepsy (n = 7), Alzheimer’s
disease (n = 1), multiple sclerosis (n = 1), and post-encephalitic
epilepsy (n = 1). In group 4 (ACU, n = 7) seizures were caused by
acute systemic illness (sepsis and hyponatremia) or acute CNS
disorder (acute brain infarction, encephalitis, necrotizing ence-
phalomyelitis). In addition to these four groups, three patients had
only a single seizure of unknown etiology.
2.1. CSF sampling and biochemical analyses
The CSF samples were takenwithin 48 h (mean 14.4 h) after the
seizure. The samples were stored at 70 8C prior to analysis. The
CSF levels of T-tau and P-tau(181P) were measured by a commercial
enzyme-linked immunosorbent assay, ELISA (Innogenetics, Ghent,
Belgium) according to the manufacturer’s protocol. The ELISA
analyses were done blinded to the diagnostic group. Two patients
in group 4 (ACU) and two in controls did not have enough CSF for P-
tau measurement. P-tau/T-tau ratio was also calculated.
2.2. Statistical analysis
Because the parameters were not normally distributed non-
parametric methods were used. Kruskal–Wallis ANOVA and
Mann–Whitney U-test were used to compare concentrations of
T-tau and P-tau. Frequency tables were compared with Pearson
Chi-square test (in 2  5 tables, 4 degrees of freedom) and Fisher’s
exact test (post hoc comparisons in 2  2 tables, 1 degree of
freedom) when appropriate. The correlations were calculated
using Spearman’s correlations. Statistical calculationswere carried
out using Statistica (ver. Win 5.1D, Statsoft Inc., Tulsa, OK, USA).
Findings were considered statistically signiﬁcant at p-values less
than 0.05.
3. Results
The median T-tau level was 163.1 pg/mL and P-tau 39.6 pg/mL
in all patients, and 143.5 pg/mL and 38.1 pg/mL in the controls
(Fig. 1). The median P-tau/T-tau ratio was 0.23 in the patients and
0.26 in the controls. There were no statistical differences in T-tau
(p = 0.09, ANOVA) or P-tau (p = 0.6, ANOVA) levels between
different etiologic groups and controls (Table 1). The number ofseizures, status epilepticus or the time interval between the
seizures and CSF sample did not correlate with tau concentrations
(r = 0.17 to 0.28, Spearman’s correlations).
P-tau/T-tau ratio showed signiﬁcant differences between the
groups and controls (p = 0.003, ANOVA, Table 1). The controls
differed fromgroups 1, 2 and 4 (p = 0.010–0.008Mann–WhitneyU-
test) but there was no statistical difference between the age-
matched controls and epilepsy group 3 (p = 0.7).
A concentration of T-tau above 400 pg/mL for patients over 60
years was considered abnormal as established in our laboratory.14
Previous studies have suggested that the reference values for
Table 1
The median values of total tau (T-tau), phosphorylated tau (P-tau), and P-tau/T-tau ratio in different patient groups and controls.
Group 1 (ALCO) Group 2 (SYMPT) Group 3 (EPI) Group 4 (ACU) Controls p-Value ANOVA
No of patients 15 16 13 7 31
The mean age (range) 49.5 (31–69) 60.0 (25–88) 35.9 (16–73) 45.3 (16–75) 40.3 (15–56)
T-tau, pg/mL (quartiles) 163.1 (129.3–333.3) 259.1 (115.5–518.2) 133.4 (114.9–159.2) 251.9 (127.3–388.7) 143.5 (108.1–214.9) 0.090
P-tau, pg/mL (quartiles) 36.6 (26.8–53.9) 47.6 (29.1–64.2) 37.6 (31.1–41.0) 38.7 (34.2–50.6) 38.1 (31.3–51.6) 0.600
P-tau/T-tau ratio (quartiles) 0.217 (0.164–0.243) 0.202 (0.135–0.242) 0.266 (0.244–0.327) 0.191 (0.093–0.232) 0.256 (0.238–0.314) 0.003
The mean time intervala
hours (range)
14.2 (4–24) 14.5 (3–48) 16.5 (6–48) 12.7 (5–24)
Group 1 (ALCO), alcoholwithdrawal; group 2 (SYMPT), remote symptomatic epilepsy; group 3 (EPI), cryptogenic focal, or idiopathic epilepsy; group 4 (ACU), acute systemic or
CNS illness.
a Time interval between seizure and LP.
Table 2
Characteristics of the patients with elevated total tau (T-tau) levels.
Patients, age Diagnosis, etiology of epilepsy T-tau (pg/mL) P-taua (pg/mL) P-tau/T-tau ratio
Group 1 (ALCO)
No 1, 44 years Alcoholic encephalopathy 692.0 36.6 0.053
No 2, 69 years Wernicke’s encephalopathy 512.3 74.8 0.146
No 3, 41 years Alcohol withdrawal 403.4 69.2 0.172
Group 2 (SYMPT)
No 4, 88 years Alzheimer’s disease 809.0 105.2 0.130
No 5, 62 years Post-traumatic epilepsy 443.3 47.1 0.106
No 6, 86 years Post-stroke epilepsy 1687.9 59.4 0.035
No 7, 32 years Post-encephalitic epilepsy 593.1 83.4 0.141
No 8, 66 years Large inoperable pituitary adenoma 706.2 80.6 0.114
Group 4 (ACU)
No 9, 16 years Viral encephalitis 388.7 34.2 0.088
No 10, 74 years Viral encephalitis 546.6 50.6 0.093
No 11, 17 years Necrotizing encephalomyelitis 350.2 ND ND
Group 1 (ALCO), alcohol withdrawal; group 2 (SYMPT), remote symptomatic epilepsy; group 4 (ACU), acute systemic or CNS illness.
a Phosphorylated tau.
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value for patients below 60 years. However, we found no
differences in the mean levels of CSF T-tau or P-tau between
age-matched controls and patients with epilepsy group 3.
There was statistical difference in the frequency of abnormal
T-tau levels between the groups studied (p = 0.002, Pearson Chi-
square). None of the patients with epilepsy of unknown origin
(group3)or the controlshadabnormal levelsofT-tau. Threepatients
witha single seizurehadalsonormal levelsofT-tau.However, a total
of 11 patients (20%) in other groups had abnormal T-tau levels. The
characteristics of these patients are shown in Table 2.
In group 1 (ALCO) 20% had abnormal tau concentrations, and
two of them showed also brain atrophy inMRI. In group 2 (SYMPT)
tau was abnormal in 31%, and all of them showed brain pathology
in MRI; two with brain atrophy, one with old contusion and brain
atrophy, one with large basal expansion (pituitary adenoma), and
one with hippocampal atrophy after encephalitis. In group 4 (ACU)
43% had abnormal tau concentrations, two patients had acute
encephalitis and one had necrotizing encephalomyelitis due to
intrathecal cytarabine treatment for Burkitt’s lymphoma. The
controls differed from groups with either acute or remote
symptomatic seizures (groups 1, 2 and 4; p = 0.03–0.003, Fisher’s
exact test) but not from those with epileptic seizures with
unknown etiology (group 3, NS). When groups 2 (SYMPT) and 3
(EPI), i.e. epilepsy without acute illness, were compared, there was
also statistical difference in the number of abnormal T-tau
(p = 0.04, Fisher’s exact test).
4. Discussion
Our results showed that CSF tau levels were within the normal
range in patients with idiopathic or cryptogenic epilepsy, andincreased levels were only found in patients with either acute or
remote symptomatic seizures.
To our knowledge seizure related changes of CSF tau have not
been previously studied in patients with different etiologies of
epilepsy. A case report based on a single patient found a transient
elevation of CSF tau levels in one patient measured 4 days after the
seizure.15 CSF tau showed an increase at 2–3 days after acute
stroke8,16 but in traumatic brain damage and brain injury after
aortic surgery the increase in tau levels started earlier, during the
ﬁrst day.7,17,18 The time interval between LP and seizure varied
(mean 14.4 h) in our patients but no correlation between tau levels
and the time interval was observed.
Elevated CSF T-tau levels have been consistently found in AD
and have been suggested to be useful in differentiating AD from
normal ageing and depression.19 However, an overlap exists with
other neurodegenerative disorders or conditions with brain
parenchymal damage.9,20 P-tau is considered to reﬂect the
phosphorylation state of tau, being a more direct marker for AD.
Consistent with this, in patients with ischemic stroke CSF T-tau but
not P-tau levels were increased and showed correlation with the
size of the infarct, indicating that CSF T-tau reﬂects the degree of
neuronal damage.8,16 Also in Creuzfeldt–Jakob disease marked
elevation of T-tau but not P-tau levels has been reported.11 In
Kapaki’s study sensitivity and speciﬁcity of P-tau/T-tau ratio were
better in the discrimination of AD versus controls than P-tau
alone.20 The best cutoff level for this ratio was 0.169. Most of our
patients with abnormal T-tau levels had quite low P-tau and also
low P-tau/T-tau ratio indicating rather non-speciﬁc neurodegen-
erative disorder or axonal damage.
CSF T-tau has been studied in alcohol related cognitive
disorders (ARCD) in attempt to discriminate AD from other
dementias using taumeasurements. Tau pathology has been found
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nucleus basalis may develop through formation of neuroﬁbrillary
tangles.21 This may account for the higher tau values for the ARCD
patients compared with the controls22 or increased tau levels seen
in patients with alcohol dementia.23 In contrast to this, CSF tauwas
within normal levels in demented and non-demented alcoholics
compared with AD patients and controls.24 In our patients with
alcohol withdrawal seizures (group 1) 20% had elevated T-tau
levels, two with known alcoholic encephalopathy.
Increased levels of tau have also been reported in patients with
cerebral infections. In one study 18% of HIV infected patients had
increased CSF tau levels, but of those who had cerebral infections
and necrosis elevated tau levelswere found in 35%.25 In Su¨ssmuth’s
study, patients with viral encephalitis and bacterial meningitis
with meningoencephalopathic complications had elevated tau
levels.10 The authors suggested that tau may be a marker for
parenchymal involvement. Consistent with this, three patients in
group 4 (ACU) had abnormal levels of tau, two with acute viral
encephalitis, one with necrotizing encephalopathy.
Other biomarkers, mainly NSE and S-100, have been used to
assess possible brain damage after seizure. Several studies have
reported raised serum and CSF NSE levels after brief seizures as
well as after status epilepticus,3,26 but no postictal elevation of S-
100 after single seizures has been observed.4,27,28 However,
cisternal S-100 as well as NSE levels ipsilateral to the site of
seizure onset were elevated interictally in intractable temporal
lobe epilepsy.29 The reduction of endogenous tau levels protected
mice against excitotoxicity in an Alzheimer’s disease mouse
model,30 indicating that tau maymediate excitotoxicity. Therefore
high CSF tau levels after seizure could mark a poorer prognosis. In
this study, the seizures without additional pathology were not
associated with high tau levels. Furthermore, the number of
seizures or status epilepticus did not correlate with the levels of
tau.
We conclude that abnormal CSF tau levels may be found in
patients with seizures. However, acute seizure itself does not seem
to lead to the elevation of CSF tau. The presence of increased CSF
tau in a patient with epileptic seizure increases the probability of
symptomatic cause.
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